| Part Two: The Evidence. Research in support
of the Best Bet Diet |
| Vitamin D the Risk of Developing M.S.for
British Irish Migrants to Australia. |
| Ashton F. Embry, Ph.D., Reinhold Vieth, Ph.D.
and Colleen Hayes, Ph.D.m. |
Hammond et al. (2000) recently documented
that British and Irish immigrants to Queensland,
Australia, situated at latitude 12°-28°,
had a striking 75% reduction in their risk
of developing multiple sclerosis (MS) when
compared with that of their native countrymen.
Importantly, this reduction affected both
adult and child immigrants. Furthermore,
using migration data from the other Australian
provinces, they elegantly demonstrated that
the reduction in MS risk for the relatively
genetically homogeneous British and Irish
immigrants progressively lessened with increasing
latitude, finally reaching zero risk reduction
in the Hobart area of Tasmania, the highest
latitude area (42°) of Australia. These
results, which overcome weaknesses in previous
migration study designs (Gale and Martyn
1995), provide the strongest evidence to
date that an environmental factor, which
protects both adults and children against
the development of MS, is abundant in Queensland
at latitude 12°-28°, but lacking
in Tasmania at latitude 42°.
Identifying this unknown protective
factor,
which has been postulated for many
years
(Visscher et al. 1977), is crucial,
because
it could suggest how to prevent MS
in susceptible
individuals living at higher latitudes.
Although Hammond et al. (2000) did
not attempt
to interpret the nature of the protective
factor, they provided an important
new clue:
the factor must benefit both children
and
adults, in addition to varying substantially
and systematically with latitude.
One prevalent interpretation is that
the
latitude-linked protective factor may
be
early contraction of a common transmissible
agent such as Epstein-Barr virus (Gale
and
Martyn 1995). This interpretation is
inconsistent
with the Hammond et al. (2000) finding
that
the protective factor is effective
for adult
immigrants.
We would like to point out that a hypothesis
involving vitamin D supply as a protective
factor is entirely compatible with
the results
of Hammond et al. (2000). Sunlight
intensity,
and consequently the vitamin D supply,
varies
substantially and decreases systematically
with increasing latitude
(Holick 1995), and sunlight exposure
could
benefit all age groups. Furthermore,
a vitamin
D metabolite was shown to be a potent
inhibitor
of an experimental autoimmune disease
that
serves as a model for MS (Hayes in
press).
Additional studies support the concept that
vitamin D supply may be a protective factor
for MS.Sunlight intensity and therefore the
vitamin D supply varies substantially with
season. In Queensland (12°-28°) vitamin
D synthesis occurs year-round, but in Tasmania
(42°), there is not enough sunlight intensity
for vitamin D synthesis from November through
February (Webb et al. 1988). Embry et al.
(in press) pointed out that the nadir in
vitamin D supplies correlated with both the
peak of MS lesion activity in German MS patients
(Auer et al. 2000) and the peak of MS disease
onset in Switzerland (Wüthrich and Rieder
1970).
Another relevant study is a very large
and
well-controlled epidemiological survey
(Freedman
et al. 2000) that demonstrated that
individuals
who had the highest residential and
occupational
sunlight exposure had a substantially
lower
mortality risk from MS (odds ratio
0.24).
The beneficial effects of sunlight
exposure
as regards MS mortality risk were independent
of country of origin, age, sex, race,
and
socioeconomic status.
It is unlikely that some other aspect of
sunlight, as suggested by Hutter and Laing
(1996) and McMichael and Hall (1997), will
turn out to be the
main protective factor because low
rates
of MS can occur in areas with low winter
sunlight intensity, if dietary practices,
such as high fish consumption, supply
high
intakes of vitamin D (Goldberg 1974).
The robust and diverse database which
points
to vitamin D supply as a protective
factor
for MS underscores the urgent need
for further
research.
The level of vitamin D nutrition that
may
inhibit MS is not known. Studies measuring
serum 25-hydroxyvitamin D3 (25(OH)D)
(the
best indicator of current vitamin D
supplies)
in MS patients and correlating these
with
MS disease activity are needed to provide
guidance on optimal vitamin D levels
from
the perspective of established MS.
Further, clinical trials are needed
to test
improved vitamin D nutrition as a possible
MS prevention strategy, as well as
a possible
treatment for established MS.
Until such trials are conducted, clinicians
may want to monitor the vitamin D status
of their MS patients, many of whom display
reduced bone mass and high fracture rates
indicative of vitamin D deficiency (Nieves
et al. 1994), and ensure that their patients
have adequate vitamin D intakes. In low sunlight
areas (>35° lat.), an intake as high
as 3000-4000 IU/day of vitamin D (1000 IU
for children) may be required to inhibit
MS on the basis that this intake approximates
vitamin D synthesis and 25(OH)D levels in
individuals who live and work in low latitude,
sunny climates where the MS risk is lowest
(Vieth 1999). This intake is known to be
safe (Vieth 1999).
|
| References: |
Auer DP, Schumann EM, Trenkwalder C. Seasonal
fluctuations of gadolinium-enhancing magnetic
resonance imaging lesions in multiple sclerosis.
Ann Neurol 2000;47: 276-277.
Embry AF, Snowdon LR, Veith R. Vitamin D
and Seasonal Fluctuations of Gadolinium-Enhancing
Magnetic Resonance Imaging Lesions in Multiple
Sclerosis. Ann Neurol in press.
Freedman DM, Dosemeci M, Alavanja MC. Mortality
from multiple sclerosis and exposure to residential
and occupational solar radiation: a case-control
study based on death certificates. Occup
Environ Med 2000; 57: 418-421.
Gale CR, Martyn CN. Migrant Studies in Multiple
Sclerosis. Progress in Neurobiology 1995;
47: 425-448.
Goldberg P. Multiple sclerosis: Vitamin D
and calcium as environmental determinants
of prevalence (A viewpoint). Part 1: Sunlight,
dietary factors and epidemiology. International
Journal of Environmental Studies 1974; 6:
19-27.
Hammond SR, English DR, McLeod JG. The age-range
of risk of developing multiple sclerosis.
Evidence from a migrant population in Australia.
Brain 2000; 123: 968-974.
Hayes CE. Sunlight, vitamin D and multiple
sclerosis. Multiple Sclerosis in press.
Holick MF. Environmental factors that influence
the cutaneous production of vitamin D. Am
J Clin Nutr 1995; 61(3 Supplement): 638S-645S.
Hutter CD, Laing P.Multiple sclerosis: sunlight,
diet, immunology and aetiology.Med Hypotheses
1996; 46: 67-74
McMichael AJ, Hall AJ. Does immunosuppressive
ultraviolet radiation explain the latitude
gradient for multiple sclerosis? Epidemiology
1997; 8: 642-645.
Nieves J, Cosman F, Herbert J, Shen V, Lindsay
R. High prevalence of vitamin D deficiency
and reduced bone mass in multiple sclerosis.
Neurology 1994; 44: 1687-92.
Vieth R. Vitamin D supplementation, 25 hydroxyvitamin
D concentrations, and safety. Amer J Clin
Nutr 1999; 69: 842-856.
Visscher BR, Detels R, Coulson AH, Malmgren
RM, Dudley JP. Latitude, migration and the
prevalence of multiple sclerosis. Am J Epidemiol
1977; 106: 470-475.
Webb AR, Kline L, Holick MF. Influence of
season and latitude on the cutaneous synthesis
of vitamin D3: exposure to winter sunlight
in Boston and Edmonton will not promote vitamin
D3 synthesis in human skin. J Clin Endocrinol
Metab. 1988; 67:373-8.
Wuthrich R, Rieder HP.The seasonal
incidence
of multiple sclerosis in Switzerland.
Eur
Neurol.1970; 3: 257-64 |
| End Paper |
 |
|